Is Non-Preserved Latanoprost Superior to Xalatan for Treatment of Glaucoma?

September 27, 2011

Clermont Pharmaceuticals, Inc., a privately held ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma, yesterday announced positive results from a phase III trial comparing effectiveness of non-preserved latanoprost to Xalatan® (latanoprost ophthalmic solution) 0.005%, in treating patients with elevated intraocular pressure due to open-angle glaucoma.

The non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan, and was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.

Read the full release.




Jump down to form below to submit your own comments

Comments are closed.